Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

01:28 •

Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

Related Videos

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

$Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape$

Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape

Sibel Blau, MD, tells us more about IQ Oncology

Sibel Blau, MD, tells us more about IQ Oncology

Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

Sibel Blau, MD, speculates on the role of telehealth in cancer management

Sibel Blau, MD, speculates on the role of telehealth in cancer management

Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients

Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

Dan Wygal provides perspective on value-based contracting in oncology

Dan Wygal provides perspective on value-based contracting in oncology

Debra Patt, MD, on why it is important for community oncologists to partner with associations

Debra Patt, MD, on why it is important for community oncologists to partner with associations

Una Hopkins, RN, regarding cancer survivorship resulting from expanded use of immune-oncology agents

Una Hopkins, RN, regarding cancer survivorship resulting from expanded use of immune-oncology agents

Brad Prechtl tells how his practice is working to improve cancer care

Brad Prechtl tells how his practice is working to improve cancer care

Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

Deborah Korenstein, MD, on the benefits & harm of overuse of health services in cancer care

Deborah Korenstein, MD, on the benefits & harm of overuse of health services in cancer care

Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer